Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NYSE:NIO NYSE:TWLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$69.38+1.6%$59.59$30.04▼$78.48$6.21B1.843.01 million shs2.52 million shsNIONIO$6.79-5.5%$6.37$3.02▼$8.02$14.99B1.386.75 million shs56.35 million shsTWLOTwilio$107.95-2.3%$105.40$69.40▼$151.95$16.96B1.252.93 million shs1.75 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+1.60%-1.76%+23.32%+25.83%+45.07%NIONIO-5.44%-9.40%+9.26%+64.88%+16.98%TWLOTwilio-2.37%+0.24%+5.51%-11.65%+52.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$69.38+1.6%$59.59$30.04▼$78.48$6.21B1.843.01 million shs2.52 million shsNIONIO$6.79-5.5%$6.37$3.02▼$8.02$14.99B1.386.75 million shs56.35 million shsTWLOTwilio$107.95-2.3%$105.40$69.40▼$151.95$16.96B1.252.93 million shs1.75 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+1.60%-1.76%+23.32%+25.83%+45.07%NIONIO-5.44%-9.40%+9.26%+64.88%+16.98%TWLOTwilio-2.37%+0.24%+5.51%-11.65%+52.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.42Hold$71.713.35% UpsideNIONIO 2.15Hold$6.35-6.41% DownsideTWLOTwilio 2.69Moderate Buy$130.2220.63% UpsideCurrent Analyst Ratings BreakdownLatest NIO, TWLO, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025CRSPCRISPR TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$75.0010/10/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.0010/8/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NIONIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TWLOTwilioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/30/2025TWLOTwilioWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$130.009/30/2025TWLOTwilioWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$130.009/27/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NIONIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TWLOTwilioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/26/2025TWLOTwilioRosenblatt SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$140.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M169.13N/AN/A$22.64 per share3.06NIONIO$9.01B1.57N/AN/A$0.40 per share16.96TWLOTwilio$4.46B3.72$2.40 per share45.04$52.11 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)NIONIO-$3.06B-$1.60N/AN/AN/A-34.71%-589.46%-23.54%11/19/2025 (Estimated)TWLOTwilio-$109.40M$0.12899.6546.733.420.43%2.78%2.26%10/30/2025 (Confirmed)Latest NIO, TWLO, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025CRSPCRISPR Therapeutics-$1.32N/AN/AN/A$8.74 millionN/A10/29/2025Q3 2025TWLOTwilio$1.05N/AN/AN/A$1.25 billionN/A9/2/2025Q2 2025NIONIO-$0.30-$0.32-$0.02-$0.32$20.07 billion$2.65 billion8/7/2025Q2 2025TWLOTwilio$1.02$1.19+$0.17$0.14$1.19 billion$1.23 billion8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANIONION/AN/AN/AN/AN/ATWLOTwilioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A16.6116.61NIONION/A0.840.71TWLOTwilio0.124.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NIONIO48.55%TWLOTwilio84.27%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%NIONIO1.00%TWLOTwilio4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionableNIONIO45,6352.09 billion2.07 billionOptionableTWLOTwilio5,535153.43 million146.53 millionOptionableNIO, TWLO, and CRSP HeadlinesRecent News About These CompaniesWhy Twilio (TWLO) Dipped More Than Broader Market TodayOctober 14 at 7:00 PM | zacks.comTwilio to Announce Third Quarter 2025 Results on October 30, 2025October 14 at 4:18 PM | tmcnet.comTwilio to Announce Third Quarter 2025 Results on October 30, 2025October 14 at 4:05 PM | businesswire.comA Look Back at Software Development Stocks’ Q2 Earnings: Twilio (NYSE:TWLO) Vs The Rest Of The PackOctober 14 at 6:48 AM | finance.yahoo.comLegal Advantage Investments Inc. Invests $995,000 in Twilio Inc. $TWLOOctober 12 at 6:44 AM | marketbeat.comBoard of the Pension Protection Fund Purchases Shares of 6,100 Twilio Inc. $TWLOOctober 12 at 5:55 AM | marketbeat.comTwilio Inc. $TWLO Position Boosted by Vontobel Holding Ltd.October 12 at 3:50 AM | marketbeat.comTwilio (TWLO): Exploring Valuation as Revenue Growth Drives Renewed Investor InterestOctober 10, 2025 | finance.yahoo.comTwilio Inc. $TWLO Shares Sold by Blair William & Co. ILOctober 10, 2025 | marketbeat.comValeo Financial Advisors LLC Takes Position in Twilio Inc. $TWLOOctober 10, 2025 | marketbeat.comWhy Twilio (TWLO) is a Top Momentum Stock for the Long-TermOctober 9, 2025 | zacks.comTwilio Inc. (TWLO) is Attracting Investor Attention: Here is What You Should KnowOctober 9, 2025 | zacks.comTwilio (NYSE:TWLO) Earns Hold (C-) Rating from Weiss RatingsOctober 8, 2025 | marketbeat.comWhy Twilio (TWLO) is a Top Growth Stock for the Long-TermOctober 8, 2025 | zacks.comTwilio (NYSE:TWLO) CEO Khozema Shipchandler Sells 12,922 SharesOctober 8, 2025 | insidertrades.comWhy Twilio (TWLO) Dipped More Than Broader Market TodayOctober 7, 2025 | zacks.comTwilio (NYSE:TWLO) CEO Sells $1,345,050.98 in StockOctober 7, 2025 | marketbeat.comKnights of Columbus Asset Advisors LLC Purchases Shares of 38,668 Twilio Inc. $TWLOOctober 6, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Increases Stake in Twilio Inc. $TWLOOctober 6, 2025 | marketbeat.comMy 3 Favorite Stocks to Buy Right NowOctober 4, 2025 | fool.comTwilio Inc. $TWLO Shares Sold by J. Safra Sarasin Holding AGOctober 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO's New Dawn: Why Wall Street's Bullish Turn Signals a ComebackBy Jeffrey Neal Johnson | September 19, 20253 Emerging Stocks You Haven't Heard Much From This CycleBy Gabriel Osorio-Mazilli | September 29, 2025Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?By Leo Miller | September 28, 2025Banks Boost Gold Forecasts: One Sees +30% Bull-Case PotentialBy Leo Miller | September 22, 2025Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI AmbitionsBy Jeffrey Neal Johnson | September 27, 2025NIO, TWLO, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$69.38 +1.09 (+1.60%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$69.80 +0.42 (+0.61%) As of 10/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.NIO NYSE:NIO$6.78 -0.40 (-5.50%) Closing price 10/14/2025 03:58 PM EasternExtended Trading$6.86 +0.07 (+1.03%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Twilio NYSE:TWLO$107.95 -2.58 (-2.34%) Closing price 10/14/2025 03:58 PM EasternExtended Trading$107.64 -0.31 (-0.29%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Twilio Inc., together with its subsidiaries, provides customer engagement platform solutions in the United States and internationally. It operates through two segments, Twilio Communications and Twilio Segment. The company provides various application programming interfaces and software solutions for communications between customers and end users, including messaging, voice, email, flex, marketing campaigns, and user identity and authentication. It also offers software products to build direct, personalized relationships with their end users, such as segment, a platform that provides tools for first-party data by unifying real-time information collected; and engage, an automation platform for the delivery of omnichannel campaigns. Twilio Inc. was incorporated in 2008 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
